Cellectis price target lowered to $4 from $5 at Barclays

Barclays lowered the firm’s price target on Cellectis (CLLS) to $4 from $5 and keeps an Overweight rating on the shares. The company’s Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.